What Drug Developers Should Look for in a Long-Term Biologics Manufacturing Partner

Key Takeaways

• Long-term biologics CDMO selection should evaluate a provider’s ability to anticipate future technical, regulatory, capacity, and commercial requirements in addition to its ability to execute the immediate manufacturing scope.

• Relevant manufacturing experience provides value when CDMO teams can apply prior knowledge to identify risks, distinguish adaptable processes from genuine constraints, and develop product-specific solutions.

• Strong CDMO partnerships manage development uncertainty through explicit assumptions, phased commitments, transparent communication, and ongoing capacity planning as clinical and commercial requirements become clearer.

• Drug developers should examine how commercial commitments are transferred from business development into project management, technical operations, quality, and manufacturing before selecting a long-term CDMO partner.

• A sustainable biologics manufacturing relationship depends on technical fit, commercial alignment, knowledge continuity, and realistic capacity planning. A single-campus model can further support continuity by eliminating shipments between drug substance and drug product facilities and between clinical and commercial manufacturing sites.

Selecting a contract development and manufacturing organization (CDMO) often begins with a relatively concrete set of questions. Does the provider have the required technologies, equipment, capacity, quality systems, and experience? Can it accommodate the current process and meet the next development milestone on the required timeline? Those questions establish technical feasibility, but they provide only part of the information needed when the intention is to build a manufacturing relationship that may continue through several clinical phases and into commercialization.

A longer-term evaluation requires looking beyond the process as it exists today. Biologics programs can change substantially as clinical information accumulates, manufacturing experience grows, and commercial requirements become clearer. Batch sizes may increase, process steps may need optimization, the final presentation may change, and regulatory expectations can introduce new work. Commercial demand may eventually look very different from the assumptions made during early development. A manufacturing partner therefore needs the ability to anticipate potential bottlenecks and regulatory challenges, recognize where current choices could constrain later options, and adapt as the program evolves.

The drug developer remains responsible for establishing the direction of the program and the objectives that the manufacturing strategy must support. The CDMO contributes by helping translate those objectives into a practical path from clinical-scale manufacturing toward larger-scale production. Early in development, it may be impossible to predict eventual demand in terms of millions of vials or syringes or the precise amount of drug substance (DS) that will be required commercially. Maintaining visibility into the range of plausible future requirements can still help teams avoid choices that unnecessarily restrict later options.

Long-term partner selection therefore involves evaluating more than the next scope of work. It requires understanding whether the organization has the judgment and flexibility to remain suitable as the product and its manufacturing requirements develop.

Technical fit remains fundamental to selection criteria, but evaluating it requires more than comparing a process description against a list of installed equipment. A CDMO needs to understand where the program stands, what manufacturing has already been completed, what limitations have emerged, which product attributes and specifications must be achieved, and what the eventual manufacturing demand could look like. A process that is adequate for an early clinical batch may rely on technologies or materials that become restrictive when volumes increase or commercial supply begins.

Experience across products and modalities helps manufacturing teams distinguish between elements that can transfer readily and those that require product-specific development. Prior knowledge of cell lines, manufacturing platforms, purification approaches, analytical strategies, materials, and scale-up behavior can reduce unnecessary exploratory work. Applying that knowledge still requires technical judgment. Even where a platform exists, experienced teams must determine how closely a new product fits and where adaptation is necessary.

The same principle applies to infrastructure. Existing equipment is especially important when near-term manufacturing is required, but a long-term relationship may justify modifications or additional equipment when the technical feasibility, timing, investment, and scale of the opportunity support the decision. Some prospective programs arrive with requirements that do not fit perfectly into the current manufacturing environment. The useful question is whether that mismatch reflects a fundamental technical limitation or a constraint that can reasonably be addressed through development, engineering, or investment.

The expertise of the people assessing the program can therefore matter as much as the equipment itself. Technical teams should be able to explain why a proposed approach is appropriate, where its limits are, what risks they anticipate, and which constraints may be solvable. That depth of reasoning provides a better indication of future adaptability than a capability list alone.

Long-term biologics manufacturing plans are built while important variables remain unresolved. Clinical programs can fail or change direction. Funding can fluctuate. Dose, presentation, process, and forecast assumptions can evolve. Approval timelines are uncertain, and commercial demand may remain difficult to estimate until relatively late in development.

A productive manufacturing relationship needs a disciplined way to work with that uncertainty. One practical approach is to make assumptions explicit. A CDMO may need an estimate of future volume to evaluate capacity or investment even when the drug developer cannot yet provide a reliable commercial forecast. Both parties can identify what is currently known, agree on reasonable working assumptions, and record those assumptions in proposals and agreements. As better information becomes available, the assumptions can be revisited rather than allowed to harden into expectations that no longer fit the program.

The structure of the engagement can also preserve flexibility. Work may be divided into defined phases or packages, with commitments increasing as milestones are reached and uncertainty decreases. That can limit the financial exposure of a drug developer whose program may change or stop, while allowing the CDMO to avoid reserving future manufacturing capacity indefinitely for work that may never materialize.

This is an important distinction in evaluating claims of flexibility. A useful partner should be able to explain which decisions must be made now, which can remain open, what assumptions support the current plan, and what events would trigger a change in scope, capacity, technology, or investment.

Reliability, transparency, and communication appear in almost every description of a strong outsourcing relationship. Their prevalence makes them difficult to use as meaningful selection criteria unless a drug developer can identify observable evidence behind the claims.

Some of that evidence should appear during diligence. A prospective client can ask who will actually manage the program, which subject matter experts will participate, when technical functions become involved, how frequently teams communicate, and how problems are escalated. A CDMO that can provide visibility into the project structure and the people responsible for execution gives the client more to assess than a general assurance that communication will be strong.

The content of early discussions can be equally revealing. A provider that raises realistic limitations, challenges assumptions, and identifies foreseeable risks before contracting demonstrates a different type of transparency from one that focuses primarily on presenting the project as straightforward. Timelines and responsibilities should be clear enough that both organizations understand where uncertainty remains and who will make decisions if the original plan changes.

Continuity among the people involved also matters. Stable teams accumulate knowledge about why decisions were made, what alternatives were evaluated, and how the client prefers to work. Different drug developers bring very different internal capabilities and working styles. Some want a CDMO to take substantial technical leadership, while others want their own scientists deeply involved in development. A mature partner should be capable of establishing a collaboration model appropriate to the particular client and project.

The value of transparency becomes clearest once an actual technical problem occurs, but selection happens before that test is available. Access to the execution team, realistic discussion of risk, clear escalation pathways, and consistency between commercial and technical conversations can provide useful advance signals.

One of the most consequential interfaces in a CDMO relationship appears before manufacturing begins: the transition from business development into technical execution.

Business development sits between what the client wants to achieve and what the manufacturing organization can realistically deliver. The role includes advocating for the client’s priorities within the CDMO while also setting realistic expectations with the client. When a requested approach initially appears incompatible with current operations, the next step should be to understand the reason for the limitation and determine whether another workable technical or commercial solution exists.

Several recent customer discussions have demonstrated that apparent manufacturing constraints may reflect specific operational assumptions rather than fundamental limitations. A thorough technical and commercial review can identify alternative approaches, process adaptations, or targeted investments that enable a suitable long-term solution. The key is to understand the customer’s underlying requirements and evaluate how best to meet them within the broader context of the program.

These discussions also highlight a limitation of relying too heavily on a request for proposal (RFP). The requested scope may describe the desired output without identifying the most practical route to producing it. Operations may see risks that were not apparent when the request was written, while the client may have business requirements that are not obvious from the technical description. Bringing those perspectives together before commitments are finalized can reduce the risk that the commercial proposal and operational reality diverge later.

Once a program begins, that alignment needs an organizational structure capable of maintaining it. At IDT Biologika, programs can include a dedicated program manager and cross-functional project team spanning process development, analytical functions, quality assurance, drug substance (DS) production, drug product (DP) engineering and manufacturing, testing, and supporting functions. Teams work against a common project plan and milestones, supported by internal and joint steering committees and a shared quality framework.

For companies evaluating CDMOs, the seam between sales and execution deserves explicit scrutiny. When do operations become involved? Do the technical teams agree with the assumptions behind the proposal? How are commitments and unresolved risks transferred to program management? Who owns the scope after contract signature? The answers can indicate whether the organization is selling an individual project or building a relationship its operational teams are prepared to sustain.

Near-term capacity is essential when a batch must be scheduled, but an open manufacturing slot does not establish that the CDMO can support the same product several years later. Batch sizes, production frequency, presentation, and commercial demand may all change as the program advances.

CDMO capacity planning is inherently dynamic. Providers support multiple customers at different stages of development, and each program can progress, expand, pause, or stop. Capacity therefore must be managed through a rolling process in which forecasts and commitments are revisited as the probability, scale, and timing of future demand become clearer.

Drug developers should understand how that process works before assuming that successful early manufacturing guarantees access to later commercial capacity. Useful diligence questions include how forecasts are updated, when tentative demand becomes a firmer reservation, how the provider manages transitions between scales, and whether expansion or equipment investment is possible if a program grows beyond its original assumptions.

Early discussions can remain useful even when exact numbers are unavailable. Understanding whether a product could ultimately require thousands, millions, or tens of millions of units can influence the suitability of the manufacturing strategy, the infrastructure required, and the way that both parties approach future investment.

The important selection criterion is the quality of the provider’s capacity-planning process and its ability to maintain an evolving conversation about future demand.

A biologics manufacturing partnership must also remain commercially workable for both organizations. Scope, price, capacity commitments, timing, and investment requirements can become sources of friction if the assumptions behind them are poorly understood from the beginning.

Commercial fit therefore belongs alongside technical fit during partner selection. The CDMO must determine whether the project makes sense within its manufacturing environment, capabilities, capacity, resource requirements, and investment priorities. The client needs confidence that the provider can meet its technical, scheduling, and financial requirements over the relevant period. A durable relationship depends on enough alignment that both parties can continue supporting the program as the scope changes.

Quoted manufacturing price remains an important part of that evaluation, particularly for products with substantial cost pressure, but comparisons should also account for the conditions surrounding the price. Geographic location, manufacturing technology, timing, capacity reservations, flexibility, infrastructure, and labor structure all affect the economics of manufacturing.

Other potential burdens should also enter a long-term comparison. Technology transfer, repeated analytical or development work, additional project-management requirements, logistics, investigations, schedule disruption, and potential future technology transfers all require resources. Their eventual impact cannot always be predicted or reduced to a single number during the RFP process, but ignoring them can produce an incomplete comparison of alternative outsourcing strategies.

A sound commercial relationship starts with realistic scope and clear assumptions. The CDMO needs to understand the resources and costs behind the work it proposes, while the client needs visibility into what supports the price, schedule, and capacity commitment. That foundation makes later changes easier to address without repeatedly reopening fundamental disagreements about the original deal.

Accumulated product and process knowledge is another important consideration in a long-term manufacturing relationship.

Technology-transfer packages can communicate specifications, procedures, batch records, and development data, but they do not always preserve the full reasoning behind previous choices. Late-stage transfers sometimes arrive with unresolved process challenges, and the receiving CDMO may have limited access to the history needed to understand why a process behaves as it does. Even extensive manufacturing experience cannot recreate missing information about what was tried, what failed, how prior batches behaved, or why particular parameters were selected. Additional testing and development may then be necessary before the receiving team can confidently improve the process.

Technology transfer will remain an important part of biologics manufacturing, and companies may change CDMOs for many valid reasons, including capacity, geography, business strategy, technical requirements, or the need for additional expertise. The experience of late-stage transfers nevertheless highlights the value of preserving process history and technical rationale throughout development, particularly when a manufacturing relationship is intended to extend across multiple stages of the product life cycle.

Experience across different product types can help manufacturing teams anticipate challenges that may emerge as a program advances. At IDT Biologika, we have supported programs ranging from vaccines and recombinant proteins to viral vectors, oncolytic viruses, monoclonal antibodies, biosimilars, and sterile injectable products. That breadth of experience helps our teams recognize potential scale-up, technology transfer, and life cycle management challenges while accounting for the specific characteristics of each product. For example, sensitive viral products may benefit from continuity across manufacturing and handling because temperature, mechanical stress, transport, and storage can affect material performance.

An integrated provider can reduce interfaces by supporting development, DS, DP, analytics, and later manufacturing activities within the same organization, although every program does not require the same service model. The physical arrangement of those capabilities also matters. When activities are distributed across sites, transitions from DS to DP manufacturing or from clinical to commercial production can introduce additional shipments, handling steps, and logistical coordination.

At IDT Biologika, all manufacturing activities are performed on a single campus. This arrangement eliminates the need to ship material between separate DS and DP facilities or between clinical and commercial manufacturing sites, distinguishing IDT from CDMOs that rely on distributed manufacturing networks. For programs that remain on campus as they advance, the model supports continuity while reducing transport-related interfaces and the associated coordination.

Backing from SK Bioscience broadens that foundation through access to additional resources, international networks, and potential investment opportunities that can support IDT’s continued development over the longer term.

Several CDMOs may be technically capable of performing the same immediate scope. The harder selection decision is determining which organization will remain a good fit after the assumptions underlying that scope begin to evolve.

Individual attention matters because biologics projects rarely follow an automated path from development to commercialization. Strong execution requires technical expertise, operational discipline, commercially realistic agreements, and communication that keeps those elements aligned.

The selection process itself can provide evidence. A prospective long-term partner should seek to understand the product and its eventual objectives, identify meaningful risks, involve the appropriate technical experts, explain limitations clearly, and build a proposal around realistic assumptions. Its commercial commitments should align with what operations can deliver, and its planning processes should allow those commitments to evolve as the program becomes better defined.

For a drug developer choosing among technically qualified CDMOs, one of the most revealing questions may therefore concern a future that neither party can describe precisely today: how will this organization respond when the product, process, forecast, or business situation no longer looks like the one described in the current RFP?

The answer provides an important indication of how well the relationship is likely to hold up as the program advances.